Advance Search

Pharmacological impact of community pharmacy counselling on H. Pylori eradication and symptom improvement in peptic ulcer disease

Treesk Nooraddin Ismail
Department of Clinical Pharmacy, College of Pharmacy, Hawler Medical University, Erbil, Kurdistan Region, Iraq.
Abubakir Majeed Saleh
Department of Community Medicine, College of Medicine, Hawler Medical University, Erbil, Kurdistan Reign, Iraq.
Badraldin Kareem Hamad
Department of Pharmacology and Toxicology, College of Pharmacy, Hawler Medical University, Erbil, Kurdistan Reign, Iraq.
Keywords:
Copyright and Licensing:

Copyright (c) 2025 Treesk Nooraddin Ismail, Abubakir Majeed Saleh, Badraldin Kareem Hamad (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Share:
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Background and objective: Successful H. pylori eradication is critical for the management of peptic ulcer disease. Recent evidence suggests that community pharmacy counselling may drive better patient motivation, adherence, and clinical outcomes. This study aimed to evaluate the pharmacological impact of structured community pharmacy counseling on treatment motivation, medication adherence, H. pylori eradication, and the resolution of key symptoms in Iraqi patients with peptic ulcer disease.

Methods: This was a quantitative, randomized controlled trial conducted in Erbil City. This study carried out in selected private clinics from November 2024 to April 2025. A total of 100 patients diagnosed with Helicobacter pylori were enrolled and randomly assigned to two groups: (50 intervention group and 50 control group). Data were collected on variables including demographic information, epigastric pain, dyspepsia, heartburn, fatigue, and stool antigen test results, patient motivation, medication adherence. Statistical analysis was performed using GraphPad Prism, applying appropriate tests such as the Chi-square test and Fisher’s exact test based on the nature of the data.

Results: The study included 100 participants with a mean age of 36.55 ± 10.84 years; 58% were male and 42% were female. Patients in the intervention group showed significantly higher motivation (86% vs. 44%, P <0.0001) and better medication adherence (94% vs. 24%, P <0.0001) compared to the control group. The eradication rate of H. pylori was significantly higher in the intervention group (90%) compared to the control group (54%), with a P-value of 0.0001. Moreover, the intervention group recovered more on symptoms, including reductions in epigastric pain (64% vs. 48%, P = 0.0012), dyspepsia (80% vs. 60%, P = 0.0629), heartburn (80% vs. 60%, P = 0.0167), and fatigue (76% vs. 52%, P = 0.011) compared to the control group.

Conclusion: Community pharmacy counseling significantly improves patient motivation and adherence, leading to superior H. pylori eradication and symptom relief. Our findings advocate for the integration of structured pharmacy counseling in to peptic ulcer disease management protocols.

PDF
PDF

Metrics

Metrics Loading ...

References

  1. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report. Gut. 2017; 66(1):6–30. https://doi.org/10.1136/gutjnl-2016-312288.
  2. Noto JM, Peek RM. The role of Helicobacter pylori in oncogenesis. Gastroenterol Clin North Am. 2017; 46(3):605–20. https://doi.org/10.1016/j.gtc.2017.05.004.
  3. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017; 153(2):420–9. https://doi.org/10.1053/j.gastro.2017.04.022.
  4. Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022; 71(10):1724–62. https://doi.org/10.1136/gutjnl-2022-327745.
  5. Naylor GM, Axon ATR. Role of Helicobacter pylori in gastro-duodenal disease: implications for management. BMJ. 2018; 361:k1984.
  6. Waskito LA, Salama NR, Yamaoka Y. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2018; 23(1):e12516. https://doi.org/10.1111/hel.12516.
  7. De Brito BB, da Silva FAF, Soares AS, Pereira VA, Santos ML, Sampaio MM, et al. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World J Gastroenterol. 2019; 25(37):5578–89. https://doi.org/10.3748/wjg.v25.i37.5578.
  8. Zamani M, Ebrahimtabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018; 47(7):868–76. https://doi.org/10.1111/apt.14561.
  9. Liu X, Wang R, Zhang L, Lu H. Helicobacter pylori and cardiovascular diseases: a systematic review. Helicobacter. 2022; 27(2):e12844. https://doi.org/10.1111/hel.12967.
  10. Salama NR, Hartung ML, Müller A. Life in the human stomach: persistence strategies of Helicobacter pylori. Nat Rev Microbiol. 2018; 16(6):386–96. https://doi.org/10.1038/nrmicro3016
  11. Mégraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev. 2021; 34(2):e00116-20. https://doi.org/10.1128/CMR.00033-06
  12. Yassin MM, Othman SM, Hama HA. Prevalence of Helicobacter pylori infection in Erbil city, Kurdistan region, Iraq. Zanco J Med Sci. 2018; 22(1):122–30. https://doi.org/10.15218/zjms.2016.0039
  13. World Health Organization. The role of the pharmacist in the healthcare system. Geneva: WHO; 2020. Available from: https://www.who.int/publications/i/item/9789241062107.
  14. Kim SY, Kim JH, Kim N. Update on the diagnosis and treatment of Helicobacter pylori infection. Korean J Intern Med. 2020; 35(1):25–41. https://doi.org/10.1007/s11938-020-00300-3.
  15. Wang YK, Kuo FC, Liu CJ, Wu MC, Shih HY, Wang SS, et al. Diagnosis of Helicobacter pylori infection: current options and developments. World J Gastroenterol. 2020; 26(32):3838–53. https://doi.org/10.3748/wjg.v21.i40.11221.
  16. World Health Organization. WHO report on antimicrobial resistance surveillance. Geneva: WHO; 2021. Available from: https://www.who.int/publications/i/item/9789240064883.
  17. World Health Organization. WHO guidelines on ethical issues in public health surveillance. Geneva: WHO; 2017. Available from: https://www.who.int/publications/i/item/9789241550199.
  18. World Health Organization. Global Health Observatory Data Repository: Peptic ulcer disease. Geneva: WHO; 2019. Available from: https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/peptic-ulcer-disease.
  19. Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, et al. Management of Helicobacter pylori infection—the Maastricht VI/Florence consensus report. Gut. 2022; 71(9):1724–62. https://doi.org/10.1136/gutjnl-2022-327745.
  20. Alshehri AA, Jalal Z, Cheema E, Haque MS, Jenkins D, Yahyouche A. Impact of the pharmacist-led intervention on the control of medical cardiovascular risk factors for the primary prevention of cardiovascular disease in general practice: A systematic review and meta-analysis of randomised controlled trials. Br J Clin Pharmacol. 2020; 86(1):29–38. https://doi.org/10.1111/bcp.14164.
  21. Schwarzer R. Health Action Process Approach (HAPA) as a theoretical framework to understand behavior change. Health Psychol Res. 2016; 4(2):e6028. https://doi.org/10.15517/ap.v30i121.23458
  22. Xiong W, Sun Y, Ding X, Wang M, Zeng Z. Selective pressure of antibiotics on ARGs and bacterial communities in manure-polluted freshwater-sediment microcosms. Front Microbiol. 2015; 6:194. https://doi.org/10.3389/fmicb.2015.00194.
  23. Cortés P, Nelson AD, Bi Y, Stancampiano FF, Murray LP, Pujalte GGA, et al. Treatment approach of refractory Helicobacter pylori infection: a comprehensive review. J Prim Care Community Health. 2021; 12:21501327211014087. https://doi.org/10.1177/21501327211014087.
  24. Saracino IM, Pavoni M, Zullo A, Fiorini G, Saccomanno L, Lazzarotto T, et al. Antibiotic resistance and therapy outcome in H. pylori eradication failure patients. Antibiotics (Basel) 2020; 9(3):121. https://doi.org/10.3390/antibiotics9030121.
  25. U.S. Food and Drug Administration. Guidance for industry: Irritable Bowel Syndrome—Clinical Evaluation of Drugs for Treatment. Silver Spring (MD): U.S. Department of Health and Human Services; 2012. Available from: https://www.fda.gov/media/73849/download.
How to Cite
Nooraddin Ismail, T. ., Majeed Saleh, A. ., & Kareem Hamad, B. (2025). Pharmacological impact of community pharmacy counselling on H. Pylori eradication and symptom improvement in peptic ulcer disease. Zanco Journal of Medical Sciences (Zanco J Med Sci), 29(3), 733–744. https://doi.org/10.15218/zjms.2025.077

Send mail to Author

Send Cancel